Aratana Therapeutics to Participate in Two Upcoming Investor Conferences

KANSAS CITY, Kan., June 19, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will participate in two upcoming investor conferences.  Aratana will provide an overview of its business during a live presentation at the JMP Securities Healthcare Conference and will be available to participate in one-on-one meetings with investors who are registered to attend either conference.

Event:


Guggenheim Animal Health Day

Date: 


Monday, June 23, 2014 

Location:


New York, NY




Event:


JMP Securities Healthcare Conference

Date: 


Tuesday, June 24, 2014 

Time: 


9:30 am (Eastern Time) 

Location:


The Westin Grand Central, New York, NY

The JMP Securities Healthcare Conference will be webcast live and will remain available for 30 days following the presentations.  To access the webcast, please visit the Investors section of the Aratana website: www.aratana.com.

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company's pipeline includes more than fifteen product candidates targeting pain, inappetance, cancer, viral diseases, allergy and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.

For investor inquires:

Craig Tooman
Chief Financial Officer
ctooman@aratana.com; (913) 951-2132

For media inquiries:
Tiberend Strategic Advisors, Inc.

Andrew Mielach
amielach@tiberend.com; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.